Outcomes of diuretic use in pre-dialysis CKD patients with moderate renal deterioration attending tertiary care referral center

Clinical and Experimental Nephrology

Volumn 21, Issue 6, 2017, Pages 1011-1023

  Khan, Yusra Habib ^a,b   Sarriff, Azmi ^a   Adnan, Azreen Syazril ^b   Khan, Amer Hayat ^a   Mallhi, Tauqeer Hussain ^a,b  

^a SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

^b SCHOOL OF PHYSICS   (Malaysia)

Author keywords

Bioimpedance analysis; Blood pressure; Chronic kidney disease; Diuretics; Fluid overload

Indexed keywords

DIURETIC AGENT; FUROSEMIDE; HYDROCHLOROTHIAZIDE; LOOP DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

ADULT; ARTICLE; ASTHENIA; CHRONIC KIDNEY FAILURE; CLINICAL OUTCOME; CONTROLLED STUDY; DIURETIC THERAPY; ESTIMATED GLOMERULAR FILTRATION RATE; EXTRACELLULAR FLUID; FEMALE; FOLLOW UP; HUMAN; HYPERGLYCEMIA; HYPERVOLEMIA; HYPOKALEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PATIENT REFERRAL; PHOTOSENSITIVITY; POLYURIA; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; TERTIARY CARE CENTER; AGED; BLOOD PRESSURE; DRUG EFFECT; GLOMERULUS FILTRATION RATE; UTILIZATION;

AGED; BLOOD PRESSURE; DIURETICS; FEMALE; FUROSEMIDE; GLOMERULAR FILTRATION RATE; HUMANS; HYDROCHLOROTHIAZIDE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; TERTIARY CARE CENTERS;

EID: 85014515811     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-017-1397-6     Document Type: Article

References (33)

1. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260–72.
2. Vasavada N, Saha C, Agarwal R. A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease. Kidney Int. 2003;64(2):632–40.
3. Levin A, Stevens PE. Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int. 2014;85(1):49–61.
4. Sica DA. Diuretic use in renal disease. Nat Rev Nephrol. 2012;8(2):100–9.
5. Devolder I, Verleysen A, Vijt D, et al. Body composition, hydration, and related parameters in hemodialysis versus peritoneal dialysis patients. Perit Dial Int. 2010;30(2):208–14.
6. Barbosa-Silva MC, Barros AJ. Bioelectrical impedance analysis in clinical practice: a new perspective on its use beyond body composition equations. Curr Opin Clin Nutr Metabol Care. 2005;8(3):311–7.
7. Tapolyai M, Faludi M, Réti V, et al. Dialysis patients’ fluid overload, antihypertensive medications, and obesity. ASAIO J. 2011;57(6):511–5.
8. Tapolyai M, Faludi M, Réti V et al. Volume estimation in dialysis patients: the concordance of brain-type natriuretic peptide measurements and bioimpedance values. Hemodial Int. 2013;17(3):406–12.
9. Tapolyai M, Faludi M, Dossabhoy NR et al. Diuretics and bioimpedance-measured fluid spaces in hypertensive patients. J Clin Hypertens. 2014;16(12):895–9.
10. Hung SC, Kuo KL, Peng CH, et al. Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease. Kidney Int. 2014;85(3):703–9.
11. Yilmaz Z, Yildirim Y, Oto F, et al. Evaluation of volume overload by bioelectrical impedance analysis, NT-proBNP and inferior vena cava diameter in patients with stage 3 and 4 and 5 chronic kidney disease. Ren Fail. 2014;36(4):495–501.
12. Hung SC, Kuo KL, Peng CH, et al. Association of fluid retention with anemia and clinical outcomes among patients with chronic kidney disease. J Am Heart Assoc. 2015;4(1):e001480.
13. Inker LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63(5):713–35.
14. Wilcox CS. New insights into diuretic use in patients with chronic renal disease. J Am Soc Nephrol. 2002;13(3):798–805.
15. Ellison DH, Loffing J. Thiazide effects and adverse effects insights from molecular genetics. Hypertension. 2009;54(2):196–202.
16. Dussol B, Moussi-Frances J, Morange S, et al. A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease. J Clin Hypertens. 2012;14(1):32–7.
17. Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol. 2010;56(19):1527–34.
18. Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology. 2002;96(3–4):132–43.
19. Hoshino T, Ookawara S, Miyazawa H, et al. Renoprotective effects of thiazides combined with loop diuretics in patients with type 2 diabetic kidney disease. Clin Exp Nephrol. 2015;19(2):247–53.
20. Kalra OP, Aggarwal A. Rational use of diuretics and pathophysiology of edema. Medicine, 22; 2012.
21. Asare K. Management of loop diuretic resistance in the intensive care unit. Am J Health Syst Pharm. 2009;66(18):1635–40.
22. Vasavada N, Agarwal R. Role of excess volume in the pathophysiology of hypertension in chronic kidney disease. Kidney Int. 2003;64(5):1772–9.
23. Agarwal R, Sinha AD. Thiazide diuretics in advanced chronic kidney disease. J Am Soc Hypertens. 2012;6(5):299–308.
24. Franse LV, Pahor M, Di Bari M, et al. Hypokalemia associated with diuretic use and cardiovascular events in the systolic hypertension in the elderly program. Hypertension. 2000;35(5):1025–30.
25. Davis BR, Cutler JA, Gordon DJ. Major outcomes in high risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–97.
26. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356(9227):366–72.
27. Coresh J, Wei GL, McQuillan G, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988–1994). Arch Intern Med. 2001;161(9):1207–16.
28. Hawkins RG, Houston MC. Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the United States? A hypothesis. Am J Hypertension. 2005;18(6):744–9.
29. Hayashi M, Uchida S, Kawamura T, et al. Prospective randomized study of the tolerability and efficacy of combination therapy for hypertensive chronic kidney disease: results of the PROTECT-CKD study. Clin Exp Nephrol. 2015;19(5):925–32.
30. Khan YH, Sarriff A, Adnan AS, et al. Diuretics prescribing in chronic kidney disease patients: physician assessment versus bioimpedence spectroscopy. Clin Exp Nephrol. 2016;1–9.
31. London GM. The clinical epidemiology of cardiovascular diseases in chronic kidney disease: cardiovascular disease in chronic renal failure: pathophysiologic aspects. In: Seminars in dialysis, vol 16, No. 2. Blackwell Science Inc. pp. 85–94;2003.
32. Madkour HO, Gadallah ME, Riveline B, et al. Comparison between the effects of indapamide and hydrochlorothiazide on creatinine clearance in patients with impaired renal function and hypertension. Am J Nephrol. 1995;15(3):251–5.
33. Fülöp T, Hickson DA, Wyatt SB, et al. Sleep-disordered breathing symptoms among African–Americans in the Jackson Heart Study. Sleep Med. 2012;13:1039–49.